ACTH-like Peptides Restore Brain Gene Expression After Stroke in Rats

Stroke, a leading cause of disability and death, often results from cerebral ischemia (lack of blood flow to the brain), which triggers a cascade of cellular damage and profound changes in gene expression. These genetic alterations can exacerbate injury and hinder recovery. While some treatments exist for acute stroke, there's a critical need for therapies that can mitigate the long-term molecular damage. This study specifically investigates whether ACTH-like peptides can compensate for the disrupted brain gene expression profile observed a day after experimental stroke.

The study revealed that ischemic stroke significantly altered the expression of over 1500 genes in the rat brain compared to sham controls, with many involved in inflammation and cell death pathways. In the peptide-treated group, this disruption was markedly attenuated. Inflammatory gene markers, such as IL-6 and TNF-alpha, which were upregulated by 2.5-fold in untreated stroke rats, showed a 43% reduction in expression in the ACTH-like peptide group (p<0.01). Furthermore, genes associated with neuroplasticity and repair, like BDNF, were increased by 1.8-fold compared to untreated stroke animals. > The study revealed that ACTH-like peptides normalized the expression of 85% of ischemia-disrupted genes back to near-baseline levels within 24 hours post-stroke, demonstrating a powerful compensatory effect.